India E-Pharmacies Stop-Start Scenario: Will It Scare Investors?
Court rulings and confusion have dotted the business landscape for the fledgling Indian e-pharmacy segment, which has seen significant investment flow over the recent past. Will investors stand by undeterred amid uncertainty while regulations and safeguards fall into place?
You may also be interested in...
Scrip delves into some key trends that could play out in 2020 to shape and impact Indian pharmaceutical firms. Keep an eye on opportunities in key markets like China and the US, and on private equity interest in “control deals” and trade margin-related tweaks on the Indian market.
Transaction audits are proposed as part of checks to monitor e-pharmacies in India, though there are some concerns on whether the well-meaning measure can become a source of “inspector raj” and stifle the fledgling industry.
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.